Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function

• Published in: Molecular cell Vol. 58; no. 6; pp. 925 - 934
• Main Authors: Feng, Felix Y., de Bono, Johann S., Rubin, Mark A., Knudsen, Karen E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 18.06.2015
• Subjects: chromatin; Chromatin - genetics; disease control; DNA Repair; Enzyme Inhibitors - therapeutic use; Humans; inflammation; Molecular Targeted Therapy - methods; Molecular Targeted Therapy - trends; NAD ADP-ribosyltransferase; neoplasms; Neoplasms - drug therapy; Neoplasms - genetics; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases - metabolism; therapeutics; transcription (genetics); Transcription, Genetic; Translational Medical Research - methods; Translational Medical Research - trends

Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were recently shown to have potential clinical impact in a number of disease settings, particularly as related to cancer therapy, treatment for cardiovascular dysfunction, and suppression of inflammation. The molecular basis for PARP1 inhibitor functi...